Introduction to the mechanism of action
Drugs from the calcium sensitizer class have a specific mechanism of action on the heart muscle. Unlike many other cardiotonic agents, they exert their effect by acting directly on the contractile apparatus of the cardiomyocyte. This means that the drug's site of action is located inside the muscle cell itself, at the level of its basic structural elements.
Primary target and molecular level
To understand exactly how levosimendan works, it is necessary to examine its interaction with myocardial proteins in detail.
- Binding site. The primary target for this medicinal substance is troponin C. This protein is a crucial component of actin filaments in the muscle fiber.
- Structural change. Once the levosimendan molecule binds to troponin C, a change in its conformation (spatial structure) occurs.
- Increased sensitivity. The altered conformation leads to a significant increase in the affinity of troponin C for calcium ions.
Due to this process, the interaction between contractile proteins — actin and myosin — is substantially facilitated. Most importantly, this effect is achieved at the exact same baseline concentrations of intracellular calcium.
Energy efficiency
The key result of levosimendan's action is a marked increase in the contractile force of the heart muscle. However, its main pharmacological advantage lies in its energy efficiency.
Since the drug merely increases sensitivity to already present calcium, the cell does not need to pump massive amounts of additional ions inward. The movement of ions across membranes is always an extremely energy-consuming process. The lack of need for such pumping results in an increase in contractile force without a significant rise in myocardial oxygen demand. This makes levosimendan an effective tool for supporting cardiac function.
Intracellular calcium cycle
To fully appreciate the role of levosimendan, one should examine the common final pathway for all classes of cardiotonic drugs. This pathway represents the intracellular calcium cycle, which culminates in myofibril contraction. The process consists of four sequential stages:
- Calcium influx. At the initial stage, ions penetrate inside the cardiomyocyte through specialized calcium channels in the plasma membrane. It is worth noting that this exact stage is enhanced by drugs such as dobutamine and milrinone.
- Release from storage. Calcium entering from the outside serves as a trigger. It causes a massive release of endogenous calcium from the sarcoplasmic reticulum. Inside this storage depot, calcium is stored in tight binding with a specific protein — calsequestrin.
- Activation of contraction. The released free cytosolic calcium rushes toward the contractile apparatus and binds to troponin C. It is this critical process that is modulated by levosimendan.
- Mechanical response. At the final stage, physical interaction occurs between myosin heads and actin. This leads to the ultimate contraction of the myofibrils.
Briefly: answers to topical questions
What pharmacological effects does levosimendan produce?
- Cardiotonic effect — enhancement of myocardial contractility.
- Hemodynamic unloading — reduction of cardiac workload through vasodilation.
- Metabolic effect — increased myocardial oxygen delivery and improved coronary blood flow.
Through what mechanism does levosimendan induce vasodilation?
- Mechanism of vasodilation — activation of ATP-sensitive potassium channels ($K_{ATP}$) in vascular smooth muscle cells.
- Hemodynamic consequences — dilation of systemic blood vessels with a reduction in preload and afterload, as well as dilation of coronary arteries with improved myocardial oxygenation.
What are the main indications for levosimendan use?
- Indications (indicationes) — acute heart failure (AHF), decompensation of chronic heart failure, and decompensation of severe chronic heart failure in patients receiving beta-blocker therapy.
What side effects are characteristic of levosimendan?
- Adverse reactions (effectus adversi) — during drug administration, extrasystoles, headaches, and hypotension may be observed.
What contraindications exist for prescribing levosimendan?
- Usage restrictions — levosimendan is not recommended for use in arterial hypotension caused by hypovolemia or other reversible causes; administration should only begin after correction of hypovolemia.
- During pregnancy, the drug should not be used; use is permissible only for vital indications if the benefit to the mother outweighs the risk to the fetus.
- During lactation, the drug should not be used due to the high risk of complications for the child.
It is easy to remember levosimendan's target: Sensitizer Sbinds to troponin S. And since it merely increases sensitivity, the cell does not need to spend oxygen on pumping new ions.
Class and exam questions
What is the main difference between levosimendan and dobutamine/milrinone?
Dobutamine and milrinone exert their effect at the first stage of the intracellular cycle, enhancing the influx of calcium ions through plasma membrane channels. Levosimendan, on the other hand, does not increase the amount of incoming calcium, but rather modulates the binding process of already available free cytosolic calcium to troponin C.
How does levosimendan conserve oxygen for the myocardium?
Enhancing myocardial contraction typically requires additional energy. However, levosimendan increases the affinity of troponin C for calcium, facilitating the interaction of actin and myosin at baseline ion concentrations. Since the cell does not need to expend energy on massive calcium pumping, myocardial oxygen demand does not increase.
What role does the sarcoplasmic reticulum play in cardiomyocyte contraction?
The sarcoplasmic reticulum acts as an intracellular storage depot. Calcium entering through the plasma membrane triggers the release of endogenous calcium from the reticulum, which was previously in a bound state with the protein calsequestrin.
What is the primary target for calcium sensitizers?
The primary target is troponin C, a specific protein that is an essential component of the actin filaments in the cardiomyocyte's contractile apparatus.
What else to study on this topic
- Mechanisms of cardiomyocyte plasma membrane calcium channels.
- The role of the calsequestrin protein in endogenous calcium storage.
- Pharmacodynamics of dobutamine and milrinone: effects on calcium influx.
- The spatial conformation of troponin C and the consequences of its alteration.
- Molecular bases of the interaction between myosin heads and actin.
Master the entire topic in the «Pharmacology» course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "Levosimendan" and 5,304 other subject pages
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 116 video lessons on the subject
Other topics in the section "Agents Increasing Blood Pressure (Hypertensive Agents)"
Entire section "Agents Increasing Blood Pressure (Hypertensive Agents)"Free video lessons: pharmacologyShort lessons with study notes — no registration required.
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.